Molecular Partners AG ADR (MOLN) - Net Assets
Based on the latest financial reports, Molecular Partners AG ADR (MOLN) has net assets worth $95.53 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($112.15 Million) and total liabilities ($16.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MOLN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $95.53 Million |
| % of Total Assets | 85.18% |
| Annual Growth Rate | 10.27% |
| 5-Year Change | 32.1% |
| 10-Year Change | -6.69% |
| Growth Volatility | 75.28 |
Molecular Partners AG ADR - Net Assets Trend (2013–2024)
This chart illustrates how Molecular Partners AG ADR's net assets have evolved over time, based on quarterly financial data. Also explore MOLN current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Molecular Partners AG ADR (2013–2024)
The table below shows the annual net assets of Molecular Partners AG ADR from 2013 to 2024. For live valuation and market cap data, see Molecular Partners AG ADR market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $141.64 Million | -19.72% |
| 2023-12-31 | $176.43 Million | -24.98% |
| 2022-12-31 | $235.17 Million | +119.19% |
| 2021-12-31 | $107.29 Million | +0.06% |
| 2020-12-31 | $107.22 Million | +98.05% |
| 2019-12-31 | $54.14 Million | -40.96% |
| 2018-12-31 | $91.70 Million | -21.44% |
| 2017-12-31 | $116.73 Million | -14.04% |
| 2016-12-31 | $135.79 Million | -10.54% |
| 2015-12-31 | $151.79 Million | +2.23% |
| 2014-12-31 | $148.48 Million | +207.31% |
| 2013-12-31 | $48.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Molecular Partners AG ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23224131800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.04 Million | 2.85% |
| Other Components | $383.89 Million | 271.04% |
| Total Equity | $141.64 Million | 100.00% |
Molecular Partners AG ADR Competitors by Market Cap
The table below lists competitors of Molecular Partners AG ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
$164.56 Million |
|
Capitan Mining Inc
V:CAPT
|
$164.56 Million |
|
Byggma
OL:BMA
|
$164.57 Million |
|
AFC Ajax NV
AS:AJAX
|
$164.63 Million |
|
Castles Technology Co Ltd
TW:5258
|
$164.50 Million |
|
St.Shine Optical Co Ltd
TWO:1565
|
$164.40 Million |
|
Finance of America Companies Inc
NYSE:FOA
|
$164.30 Million |
|
Endava Ltd
NYSE:DAVA
|
$164.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Molecular Partners AG ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 176,429,000 to 141,637,000, a change of -34,792,000 (-19.7%).
- Net loss of 54,043,000 reduced equity.
- New share issuances of 17,342,000 increased equity.
- Other factors increased equity by 1,909,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-54.04 Million | -38.16% |
| Share Issuances | $17.34 Million | +12.24% |
| Other Changes | $1.91 Million | +1.35% |
| Total Change | $- | -19.72% |
Book Value vs Market Value Analysis
This analysis compares Molecular Partners AG ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.77x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $2.48 | $4.40 | x |
| 2014-12-31 | $9.71 | $4.40 | x |
| 2015-12-31 | $7.77 | $4.40 | x |
| 2016-12-31 | $6.65 | $4.40 | x |
| 2017-12-31 | $5.60 | $4.40 | x |
| 2018-12-31 | $4.33 | $4.40 | x |
| 2019-12-31 | $2.53 | $4.40 | x |
| 2020-12-31 | $4.29 | $4.40 | x |
| 2021-12-31 | $3.46 | $4.40 | x |
| 2022-12-31 | $7.07 | $4.40 | x |
| 2023-12-31 | $5.38 | $4.40 | x |
| 2024-12-31 | $4.16 | $4.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Molecular Partners AG ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1087.38%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.12x
- Recent ROE (-38.16%) is below the historical average (-22.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.78% | 22.03% | 0.29x | 2.28x | $2.31 Million |
| 2014 | -1.54% | -8.57% | 0.14x | 1.31x | $-17.13 Million |
| 2015 | -0.10% | -0.51% | 0.13x | 1.45x | $-15.33 Million |
| 2016 | -13.71% | -80.78% | 0.13x | 1.36x | $-32.19 Million |
| 2017 | -21.79% | -127.05% | 0.14x | 1.24x | $-37.10 Million |
| 2018 | -40.39% | -357.66% | 0.07x | 1.69x | $-46.21 Million |
| 2019 | -67.03% | -178.03% | 0.19x | 1.94x | $-41.70 Million |
| 2020 | -58.54% | -671.70% | 0.05x | 1.75x | $-73.49 Million |
| 2021 | -59.45% | -683.65% | 0.05x | 1.61x | $-74.51 Million |
| 2022 | 50.11% | 62.17% | 0.72x | 1.12x | $94.34 Million |
| 2023 | -35.13% | -880.70% | 0.04x | 1.12x | $-79.63 Million |
| 2024 | -38.16% | -1087.38% | 0.03x | 1.12x | $-68.21 Million |
Industry Comparison
This section compares Molecular Partners AG ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Molecular Partners AG ADR (MOLN) | $95.53 Million | 14.78% | 0.17x | $164.56 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more